TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02493985

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 0.5% CO2
Description: The subjects will be randomized to breath 0.5% carbon dioxide during one of the -12 degree head down tilt body position periods in crossover design

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ambient air
Description: The subjects will be randomized to breath ambient air during one of the -12 degree head down tilt body position periods in crossover design
Study: NCT01031342

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early colonoscopy
Description: Colonoscopy within 12 hours of presentation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Elective colonoscopy
Description: Colonoscopy 36-60 hours after presentation
Study: NCT03072329

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pudendal nerve block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Study: NCT00602979

Intervention type: DEVICE
Group type: OTHER
Intervention: Macintosh laryngoscope
Description: Used during laryngoscopy to facilitate intubation.

Intervention type: DEVICE
Group type: OTHER
Intervention: Airtraq® Optical Laryngoscope
Description: Used during laryngoscopy to facilitate intubation.

Intervention type: DEVICE
Group type: OTHER
Intervention: Storz DCI Video Laryngoscope®
Description: Used during laryngoscopy to facilitate intubation

Intervention type: DEVICE
Group type: OTHER
Intervention: GlideScope® Video Laryngoscope
Description: Used during laryngoscopy to facilitate intubation

Intervention type: DEVICE
Group type: OTHER
Intervention: McGRATH® Video Laryngoscope
Description: Used during laryngoscopy to facilitate intubation
Study: NCT00995488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-007 (Abraxane®)
Description: ABI-007 is a novel albumin-bound paclitaxel combining a protein with a chemotherapeutic agent in the particle form.
Study: NCT01700972

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Myocardial perfusion imaging
Description: The radionuclide Myoview will be administered once for the rest and stress myocardial perfusion imaging. The subsequent rest and stress imaging will be performed twice each - at 10 minutes and 30-45 minutes after radiotracer injection.
Study: NCT06490055

Intervention type: DRUG
Intervention: Paclitaxel
Description: Gastric cancer second-line Chemotherapy (paclitaxel plus ramucirumab)

Intervention type: DRUG
Intervention: Paclitaxel
Description: Gastric cancer second-line Chemotherapy (paclitaxel plus ramucirumab)
Study: NCT04024670

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Arts Intervention
Description: If selected for the arts activity, an artist in residence will visit you 3 times a week for a total of 3 weeks during your hospital stay. Two visits will focus on the arts activity and one visit will be the administration of the questionnaire. Each visit will be approximately 25 minutes at a time.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Arts Intervention
Description: If selected for the arts activity, an artist in residence will visit you 3 times a week for a total of 3 weeks during your hospital stay. Two visits will focus on the arts activity and one visit will be the administration of the questionnaire. Each visit will be approximately 25 minutes at a time.
Study: NCT00856193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo capsules were supplied for inhalation once daily with Concept 1 device.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules were supplied for inhalation once daily with Concept 1 device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVA237
Description: NVA237 50 μg capsules were supplied for inhalation once daily with Concept 1 device.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NVA237
Description: NVA237 50 μg capsules were supplied for inhalation once daily with Concept 1 device.
Study: NCT01063192

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Arm 1: Gemcitabine alone on D1,8,15 every 28 days for 3 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine, Oxaliplatin, 5-Fluorouracil, Leucovorin (GOFL)
Description: Arm 2: GOFL on D1, 15 every 28 days for 3 cycles(Gem 800mg/m2 80min, Oxa 85mg/m2 2hr, 5FU 3000mg/m2, LV 150mg/m2 iv 48hr)
Study: NCT02123004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: 180mg loading dose for one day ,and then 90mg per day for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: 300mg loading dose for one day ,and then 75mg per day for 4 weeks
Study: NCT04364035

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline placebo delivered as one 0. 5 mL IM injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Unit-dose placebo tablet delivered as two 3-mg placebo tablets
Study: NCT01483131

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: 12 weeks of resistance training twice a week.
Study: NCT02871154

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Delaying oocyte pick up beyond 39 hours post hCG
Description: Unlike the traditional less-than 39 hours interval from hCG injection to oocyte pick up, we will extend the interval up to 47 hours
Study: NCT03691454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 50mg/m2, intravenous drip, D1, combined with Oxaliplatin 85mg/m2，intravenous drip 2h，D1 and S-1 40-60mg bid(BSA\<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2, 50mg bid, BSA\>1.5m2, 60mg bid)，D1-7；For patients with Her2 positive, add Herceptin 4mg/kg(6mg/kg first cycle) D1; every 14 days for a cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin 130mg/m2，intravenous drip 2h，D1 combined with S-1 40-60mg bid(BSA\<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2, 50mg bid, BSA\>1.5m2, 60mg bid)，D1-14；For patients with Her2 positive, add Herceptin 6mg/kg(8mg/kg first cycle) D1; every 21 days for a cycle.
Study: NCT05169801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BP102, paclitaxel, carboplatin
Description: BP102, paclitaxel, carboplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avastin®, paclitaxel, carboplatin
Description: Avastin®, paclitaxel, carboplatin
Study: NCT01876121

Intervention type: DRUG
Intervention: Celecoxib
Description: oral
Study: NCT02334878

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem Cells,Mesenchymal
Description: The patient will be placed in lithotomy position. A Foley's catheter (size 18) will be inserted in the urethra, then under local anaesthesia; retrieved cells (total 20- 30 million cells per patient in 10cc syringe) will be injected into the submucosal tissue at the level of the proximal urethra just distal to the bladder neck (guided by stretch on the Foley's catheter), at 3,9,12 o'clock, injecting around 3.5 cc in each site.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery (TVT)
Description: A small midurethral incision will be made in the vaginal mucosa, then a polypropylene 40\*1cm mesh tape attached to two curved trocars will be passed lateral to the urethra \& through the endopelvic fascia into the retropubic space. The trocar will then be passed along the back of the pubic bone, through the rectus fascia, in two small suprapubic skin incisions, then the tension on the tape adjusted \& the remaining tape cut off at the level of the skin.
Study: NCT02615782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-397
Description: CKD-397 1T single oral administration under fasting condition or fed condition(high fat meals)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-397
Description: CKD-397 1T single oral administration under fasting condition or fed condition(high fat meals)
Study: NCT04186793

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Grocery Shopping (GGS)
Description: The GGS group will be scheduled for 4 weekly sessions to co-shop with the study Registered Dietitian (RD) or clinical research coordinator (CRC). The primary shopper for the household will be required to attend all 4 sessions. The study participant will be required to attend at least 1 session and other family/household members will be encouraged to attend. The weekly sessions will take place at the family's primary grocery store. During each session, the RD will facilitate selection of low free sugar foods and guide the primary shopper on menu planning for a low free sugar diet. In the 4th session, the primary shopper will be asked to shop independently while being observed by the RD/CRC. Prior to checking out, the RD/CRC will approve and/or correct their shopping choices.~During the follow-up period, all participants will receive diet counseling/support calls from the dietitian and/or research team at Months 2, 4, and 6, following intervention completion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet Provision Group
Description: This intervention will be applied to each family and will target foods and beverages that contain free sugars added to food by consumer, cook, or manufacturer, but preserve the family's other food group choices. During the 4 week long intervention, families will be able to choose meals from a list of foods similar to their usual diet. Groceries for each week will be delivered to the family. Each child will be provided with a lunch bag and instructed to bring lunch to school to maintain the study diet.~Families will have the opportunity to choose from a list of pre-prepared evening meals that are similar to what they consumed before study initiation but without free sugars. The families will be instructed to not eat any food outside of the assigned diet.~During the follow-up period, all participants will receive diet counseling/support calls from the dietitian and/or research team at Months 2, 4, and 6, following intervention completion.
Study: NCT03082339

Intervention type: OTHER
Intervention: Cortisone
Description: Observation of QTc-interval

Intervention type: OTHER
Intervention: Cortisone
Description: Observation of QTc-interval
Study: NCT03175640

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Implementation intervention
Description: The implementation intervention includes peer-to-peer training, post-training outreach, proactive expert support, and assistance with addressing environmental barriers.
Study: NCT01483131

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: 12 weeks of resistance training twice a week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training with vascular occlusion
Description: 12 weeks of resistance training with vascular occlusion twice a week
Study: NCT00123240

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low calorie high carbohydrate diet
Description: 65% carbohydrate, 15% protein, 20% fat (7% SFA, 8% MFA, 4% PUFA), P/S 0.63, 152 mg cholesterol/1500 kcal

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low calorie high fat/protein diet
Description: High Fat/Protein Diet: 10% carbohydrate, 25% protein, 65% fat (26% SFA, 25% MFA, 9% PUFA), P/S 0.33, 458 mg cholesterol/1500 kcal
Study: NCT02642913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide with Sorafenib
Study: NCT02782819

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic crystalloid solution resuscitation
Description: Patient will receive normal saline or Ringer lactate or other balance salt solution during fluid resuscitation for shock reversal.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotonic crystalloid solution resuscitation
Description: Patient will receive normal saline or Ringer lactate or other balance salt solution during fluid resuscitation for shock reversal.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colloid solution resuscitation
Description: Patient will receive 5% albumin or gelatin solution during shock resuscitation
Study: NCT01639209

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vitrectomy
Description: Pars plana vitrectomy plus laser/cryotherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pneumatic retinopexy
Description: Pneumatic retinopexy plus laser/cryotherapy
Study: NCT02619045

Intervention type: OTHER
Group type: OTHER
Intervention: Telephone follow-up nursing device
Description: Telephone follow-up nursing device involving:~* telephone appointments made by a dedicated nurse and set up at key stage of treatment (1 phone call per week during chemotherapy cycles),~* specific questionnaire used by the nurse at each phone call (toxicity, general care, quality of life...),~* actions taken for the patient following each phone call (consultation with a doctor, patient hospitalization, sending of a prescription, coordination with the city medical caregiver);
Study: NCT02588118

Intervention type: DRUG
Intervention: propofol
Description: Propofol 2 mg/kg (t0) followed by cisatracurium 0.1 mg/kg 1 min (t2). Patients will be monitored using bispectral index monitoring for propofol and Relaxometer mechanomyograph neuromuscular monitoring for cisatracurium. Serial arterial blood samples (5 ml) were withdrawn in EDTA-tubes before cisatracurium administration, 1, 3, 5, 7, 10, 13, 16, 19, 22, 25, 30, 60 and 90 min following administration. Blood samples were assayed in duplicate using high performance liquid chromatograph for Pharmacokinetic analysis.
Study: NCT01586494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ULTRAM ER
Description: One dose of ULTRAM ER that is closest to 2 mg/kg, based on the participant's body weight and adjusting the dose in 25 mg increments.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ULTRAM ER
Description: The target dose for Group 2 will be the one that achieves a level of exposure similar to that seen with a single 200 mg ULTRAM ER dose in adults.
Study: NCT02588118

Intervention type: DRUG
Intervention: propofol
Description: Propofol 2 mg/kg (t0) followed by cisatracurium 0.1 mg/kg 1 min (t2). Patients will be monitored using bispectral index monitoring for propofol and Relaxometer mechanomyograph neuromuscular monitoring for cisatracurium. Serial arterial blood samples (5 ml) were withdrawn in EDTA-tubes before cisatracurium administration, 1, 3, 5, 7, 10, 13, 16, 19, 22, 25, 30, 60 and 90 min following administration. Blood samples were assayed in duplicate using high performance liquid chromatograph for Pharmacokinetic analysis.

Intervention type: DRUG
Intervention: Cisatracurium
Description: Propofol 2 mg/kg (t0) followed by cisatracurium 0.1 mg/kg 1 min (t2). Patients will be monitored using bispectral index monitoring for propofol and Relaxometer mechanomyograph neuromuscular monitoring for cisatracurium. Serial arterial blood samples (5 ml) were withdrawn in EDTA-tubes before cisatracurium administration, 1, 3, 5, 7, 10, 13, 16, 19, 22, 25, 30, 60 and 90 min following administration. Blood samples were assayed in duplicate using high performance liquid chromatograph for Pharmacokinetic analysis.

Intervention type: DRUG
Intervention: Cisatracurium
Description: Propofol 2 mg/kg (t0) followed by cisatracurium 0.1 mg/kg 1 min (t2). Patients will be monitored using bispectral index monitoring for propofol and Relaxometer mechanomyograph neuromuscular monitoring for cisatracurium. Serial arterial blood samples (5 ml) were withdrawn in EDTA-tubes before cisatracurium administration, 1, 3, 5, 7, 10, 13, 16, 19, 22, 25, 30, 60 and 90 min following administration. Blood samples were assayed in duplicate using high performance liquid chromatograph for Pharmacokinetic analysis.
Study: NCT02349711

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic mixture
Description: A 350 mg capsule containing a mixture of Lactobacillus gasseri, Bifidobacterium bifidum, and Bifidobacterium longum (1.5 billion cells per capsule prior to expiration) will be taken twice daily for 8 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded). Inactive ingredients include gelatin, potato starch, and silica.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be taken as a capsule twice daily for 8 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded). Supplement contains 348.25 mg of potato starch.
Study: NCT04432818

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pack Health's digital life coaching (DLC)
Description: Pack Health smartphone-based DLC platform will be provided for 16-week subscription which allows unlimited bidirectional communication between enrolled participants and their life coach
Study: NCT04723173

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Feature for noise reduction (on)
Description: The noise reduction feature shall support the hearing aid user in noisy situations and shall reduce the listening effort.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Feature for noise reduction (off)
Description: To show the advantage of the noise reduction feature there is a comparison without the feature necessary.
Study: NCT03500796

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Platelet rich plasma clot implantation
Description: Implantation of a platelet rich plasma clot, which is created from the plasma of the patients, and refrigerated to be inserted under the sealing amniotic membrane

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Wound closure with amniotic membrane
Description: Closure of the corneal perforation with a synthetic amniotic membrane with a 2 mm safety margin
Study: NCT03785041

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine Hydrochloride 2.5 MG/ML
Description: Intrarticular injection of tramadol in addition to levobupivacaine in different doses preemptive and postoperative
Study: NCT01979302

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Depression CAREPATH
Description: Nurses receive training and agency support in depression assessment and depression care management

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Nurses receive training in depression assessment and review of usual care procedures.
Study: NCT02542722

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: General recommendations about a healthy diet and physical activity and referral to their general physician with a report of the study results in the event of detecting any risk factor or pathological finding

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Intervention
Description: Based on office visits each 3 months during the first year, as well as monthly telephone calls during the first year. Each subject will also attend a group educational meeting each 6 months. At each visit they will be given a series of recommendations and their degree of adherence evaluated and the evolution of their weight checked. The recommendations are designed to re-educate the subjects concerning their dietary and physical activity habits
Study: NCT00934622

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcrySof® ReSTOR® Aspheric IOL
Description: AcrySof® ReSTOR® Aspheric Intraocular Lens (IOL) implanted into the study eye following the cataract extraction surgery
Study: NCT04231994

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TPE
Description: singular Therapeutic Plasma Exchange using fresh frozen Plasma as replacement fluid
Study: NCT03607656

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin powder injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin powder injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine tablet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TCM
Description: TCM decoction orally taken twice a day for at least 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-1
Description: S-1 capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1 capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel injection
Study: NCT06576336

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic adrenalectomy
Description: laparoscopic adrenalectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic adrenalectomy
Description: laparoscopic adrenalectomy
Study: NCT03607656

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: 5-FU injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 5-FU injection
Study: NCT03785041

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine Hydrochloride 2.5 MG/ML
Description: Intrarticular injection of tramadol in addition to levobupivacaine in different doses preemptive and postoperative

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine Hydrochloride 2.5 MG/ML
Description: Intrarticular injection of tramadol in addition to levobupivacaine in different doses preemptive and postoperative
Study: NCT02838329

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: warming of ropivacaine for BT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivicaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivicaine
Study: NCT03022929

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Antimicrobial Stewardship Commitment and Feedback
Description: Goes beyond the GetSmart recommendations to discern whether these recommendations can be improved upon.
Study: NCT00883259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 850 mg twice daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Microcristallyne cellulose 1 table twice daily